Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine for chemotherapy-induced peripheral neuropathy
ACTRN12617000139370Phase 2Recruiting
- Sponsor
- Prince of Wales Hospital
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of duloxetine in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms), sponsored by Prince of Wales Hospital. Primary endpoint: FACT/GOG-NTx neurotoxicity subscale. Started Sep 2017; status: recruiting.
02
Drugs
duloxetine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on ACTRN12617000139370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000139370.